Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP-6A4
- Development stage
- Preclinical
- Lead developer
- Novopyxis
- Modality
- Peptides
- Administration
- Subcutaneous, Parenteral
01
Overview
NP-6A4 is a preclinical peptide therapeutic developed by Novopyxis. It is a variant of the peptide NP-6A and acts as a selective agonist of the Angiotensin II type 2 receptor (AT2R). The drug is being investigated for its potential in treating diabetic cardiovascular complications and providing cardiovascular cell protection. Research has demonstrated its ability to protect cardiovascular cells under nutrient-starved conditions and regulate Mcl-1 for neuroprotection in dopaminergic neuronal cell lines, suggesting potential applications in neurodegenerative diseases like Parkinson's disease.
- Other names
- NP-6A variantNP6A variantNP 6A variant
02
Targets
AGTR2 (AT2)
Beyond the preview
Go deeper on NP-6A4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP-6A4.